Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-23

Clinical Trial Update: Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies [Phase 3]

View source ↗

Summary

Phase 3 study evaluating DCC-2618 (ripretinib) vs placebo in advanced gastrointestinal stromal tumor patients previously treated with anticancer therapies has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DCC-2618

Snippet

Sponsor: Deciphera Pharmaceuticals, LLC | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: COMPLETED | Results posted: 2021-04-23